Atlas Trials

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

Clinical trial NCT00229710 · TERMINATED

Trial details

NCT number
NCT00229710
Sponsor
AstraZeneca
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2005-02-01
Primary completion
2006-12-01
Enrollment
270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.